Ignite Creation Date:
2024-05-06 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 12:48 PM
Study NCT ID:
NCT03566485
Status:
TERMINATED
Last Update Posted:
2021-08-11
First Post:
2018-06-11
Brief Title:
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Vanderbilt-Ingram Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-07-10
Start Date Type:
ACTUAL
Primary Completion Date:
2020-12-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-12-10
Completion Date Type:
ACTUAL
First Submit Date:
2018-06-11
First Submit QC Date:
June 11 2018
Study First Post Date:
2018-06-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2021-08-11
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-08-10
Last Update Post Date:
2021-08-11
Last Update Post Date Type:
ACTUAL